share_log

Canaccord Genuity Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $107

Moomoo 24/7 ·  Apr 23 10:49

Canaccord Genuity analyst Sumant Kulkarni maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $100 to $107.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment